Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Watson Pharmaceuticals
A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male, at least 18 years of age
Has a total NIH-CPSI total score of 15
Has a NIH-CPSI pain score of 8
Has had pain in the pelvic region for at least 3 months prior to screening
You may not be if
Has previously participated in a Watson study with silodosin
Has previously received α-blocked therapy for chronic prostatitis/chronic pelvic pain syndrome or is currently receiving α-blocked therapy for any condition
Has experience ≥2 urinary tract infections within the previous 12 months
Has any medical condition that in the opinion of the investigator precludes safe participation in the study
Has any medical condition that could confound the efficacy evaluation
Is receiving ketoconazole, or other known potent inhibitors of cytochrome P450 3A4 or any medication in the opinion of the investigator that precludes safe participation in the study
Is receiving any medication that in the opinion of the investigator that could confound the efficacy evaluation
Has participated in a study involving the administration of an investigational agent within the past 30 days
Clareo Health | Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
